Mutation of the Highly Conserved Ser-40 of the HIV-1 p6 Gag Protein to Phe
Causes the Formation of a Hydrophobic Patch, Enhances Membrane Association,
and Polyubiquitination of Gag by Hahn, Friedrich et al.






Mutation of the Highly Conserved Ser-40 of the HIV-1 p6 Gag 
Protein to Phe Causes the Formation of a Hydrophobic Patch,  
Enhances Membrane Association, and Polyubiquitination of Gag 
Friedrich Hahn 
1
, Christian Setz 
1
, Melanie Friedrich 
1
, Pia Rauch 
1
, Sara Marie Solbak 
2
,  
Nils Åge Frøystein 
2
, Petra Henklein 
3
, Jörg Votteler 
1,†
, Torgils Fossen 
2




 Institute of Virology, Friedrich-Alexander-University, 91054 Erlangen, Germany; E-Mails: 
Friedrich.Hahn@viro.med.uni-erlangen.de (F.H.); Christian.Setz@viro.med.uni-erlangen.de (C.S.); 
Melanie.Friedrich@viro.med.uni-erlangen.de (M.F.); Pia.Rauch@viro.med.uni-erlangen.de (P.R.); 
Joerg.Votteler@biochem.utah.edu (J.V.) 
2
 Department of Chemistry and Centre for Pharmacy, University of Bergen, N-5007 Bergen, Norway;  
E-Mails: Sara.Solbak@kj.uib.no (S.M.S.); Nils.Froystein@kj.uib.no (N.Å.F.); 
Torgils.Fossen@kj.uib.no (T.F.) 
3
 Institute of Biochemistry, Charité Universitätsmedizin-Berlin, 10117 Berlin, Germany;  
E-Mail: Petra.Henklein@charite.de 
†
 Current Address: Department of Biochemistry, University of Utah School of Medicine,  
Salt Lake City, UT 84112-5650, USA. 
* Author to whom correspondence should be addressed;  
E-Mail: Ulrich.Schubert@viro.med.uni-erlangen.de; Tel.: +49-9131-8526478;  
Fax: +49-9131-8526182. 
External Editors: Charles L. Brooks and Eric R. May 
Received: 6 August 2014; in revised form: 19 September 2014/ Accepted: 26 September 2014/  
Published: 02 October 2014 
 
Abstract: The HIV-1 p6 Gag protein contains two late assembly (L-) domains that recruit 
proteins of the endosomal sorting complex required for transport (ESCRT) pathway to 
mediate membrane fission between the nascent virion and the cell membrane. It was 
recently demonstrated that mutation of the highly conserved Ser-40 to Phe (S40F) disturbs 
CA-SP1 processing, virus morphogenesis, and infectivity. It also causes the formation of 
filopodia-like structures, while virus release remains unaffected. Here, we show that the 
mutation S40F, but not the conservative mutation to Asp (S40D) or Asn (S40N), augments 
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membrane association, K48-linked polyubiquitination, entry into the 26S proteasome, and, 
consequently, enhances MHC-I antigen presentation of Gag derived epitopes. Nuclear 
magnetic resonance (NMR) structure analyses revealed that the newly introduced Phe-40, 
together with Tyr-36, causes the formation of a hydrophobic patch at the C-terminal α-helix 
of p6, providing a molecular rationale for the enhanced membrane association of Gag 
observed in vitro and in HIV-1 expressing cells. The extended exposure of the S40F 
mutant to unidentified membrane-resident ubiquitin E3-ligases might trigger the 
polyubiquitination of Gag. The cumulative data support a previous model of a so far 
undefined property of p6, which, in addition to MA, acts as membrane targeting domain of 
Gag. 
Keywords: HIV-1; Gag p6; ubiquitination; virus budding; membrane association 
 
1. Introduction 
The Gag polyprotein Pr55 of HIV-1 contains all structural components that are essential and 
sufficient for the formation of virus like particles (VLPs) [1,2]. Concurrent with virus release, Gag is 
processed by the virus encoded protease (PR) into its mature proteins matrix (MA), capsid (CA), 
nucleocapsid (NC), and the C-terminal p6 protein. 
MA mediates targeting and binding of Gag to the plasma membrane and lines the inner shell of the 
mature virus particle [3,4]. CA forms the conical core encasing NC, which itself regulates the 
packaging and condensation of the viral genome into nascent virions [5,6]. The C-terminal p6 region 
of Gag is required to detach the nascent virion from the plasma membrane by the function of its two 
late assembly (L-) domains. The primary L-domain, the tetrapeptide motif PTAP, mediates the 
recruitment of TSG101 (tumor susceptibility gene 101) to the virus budding site [7–10]. The secondary 
L-domain consists of a YPX3L motif that regulates the binding of ALIX (ALG-2 interacting protein 
1/X) to Gag [11–14]. Both proteins are components of the ESCRT (endosomal sorting complex 
 required for transport) pathway that normally mediates topologically equivalent membrane fission 
events during membrane protein trafficking and cytokinesis [15–19]. In case of ESCRT-dependent 
sorting of membrane proteins into multivesicular bodies (MVBs), mono-ubiquitination and formation 
of K63-linked poly-ubiquitin chains serves as an important signal [20]. Consistently, 
monoubiquitinated species of Gag have been described [21,22] and are believed to play a certain, so far 
enigmatic, role in the budding process [7,23–25]. Mutation of the PTAP L-domain results, besides in a 
defective virus release, in an increased Gag ubiquitination which is believed to be a consequence of an 
accumulation of Gag at the plasma membrane [26]. 
In addition, p6 represents the predominant phosphoprotein in virus particles and is a substrate for 
several virus associated kinases, among them the atypical protein kinase C (aPKC) targeting the highly 
conserved serine residue 40, and Erk-2 (extracellular signal-regulated kinase 2) targeting Thr-23 [27–29]. 
The aPKC site Ser-40 is somehow important for CA-SP1 processing, morphogenesis of progeny 
virions and virus maturation [30,31], but the molecular mechanism how this conserved Ser-40 
regulates those late processes in virus replication still remains enigmatic. However, and unlike L-
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domain mutants, the exchange of Ser-40 to Phe (S40F) causes no defect in virus release [30,31], but 
specifically induces Gag-containing membrane protrusions resembling filopodia [31]. Moreover, the 
ALIX-interacting protein syntenin [32], which is known to bind both K48- and K63-linked 
polyubiquitin [33,34], has been speculated to play a role in the process of S40F-mediated filopodia 
formation [31]. In addition, the S40F mutation interferes with the Nedd4 ubiquitin ligase mediated 
virus release [31]. Because it is also well established that phosphorylation can generally trigger 
ubiquitination [35], these cumulative results prompted us to investigate the interaction of S40F mutant 
Gag with the ubiquitin proteasome system (UPS). 
Here we show that the S40F mutation specifically leads to the formation of a hydrophobic patch on 
the C-terminal α-helix of p6 which consequently enhances the membrane interaction of Gag. This 
augmented membrane association of the S40F mutant is accompanied, similar to the mutation of the 
PTAP L-domain, by increased K48-linked polyubiquitination of Gag and, thus, enhances its entry into 
the UPS. This phenomenon provides evidence for an L-domain independent induction of Gag 
ubiquitination that might be causally linked to the formation of a cryptic membrane interaction site 
within the C-terminal α-helix of p6. In addition, the cumulative data support a previously hypothesized 
model [36] whereby, in addition to MA, p6 inserts in plane into the lipid bilayer and thus regulates the 
membrane association of Gag. 
2. Materials and Methods 
2.1. Cell Culture and Transfection 
HeLa cells were cultivated in DMEM supplemented with 10% (v/v) inactivated fetal calf serum 
(FCS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. HeLa-Kb cells were  
maintained in DMEM with additional 1 mg/mL geneticin. B3Z cells were cultured in RPMI 1640 with 
10% (v/v) FCS, 2 mM L-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, 0.01% (v/v) sodium 
pyruvate, and 10 mM HEPES. All cell culture reagents and media were purchased from Gibco (Life 
Technologies, Carlsbad, CA, USA).  
Confluent monolayers of HeLa cells were transfected with Lipofectamine 2000 (Life Technologies, 
Carlsbad, CA, USA) using the manufacturers protocol. 24 h post transfection cells were lysed in RIPA 
buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 10 
mM EDTA) containing protease inhibitor cocktail complete mini (Boehringer, Ingelheim am Rhein, 
Germany), 5 mM N-ethylmaleimide (NEM), and 1 mM phenylmethylsulfonylfluoride (PMSF) and 
protein samples were added to equal volumes of sample buffer and separated by SDS PAGE. Virus 
containing supernatants were centrifuged through 20% sucrose cushions (w/v) for 90 min at 20,000 × 
g. Pelleted VLPs were washed with 1 ml cold PBS and lysed in sample buffer. 
2.2. Detection of Ubiquitinated Gag 
HeLa cells were lysed with RIPA buffer containing protease inhibitor cocktail NEM, and PMSF. 
Lysates were adjusted to 1% SDS (w/v) and incubated at 95 °C for 10 min, subsequently diluted to 
0.1% SDS and were then cleared by centrifugation at 20,000 × g for 10 min. Gag content was 
recovered by immunoprecipitation with antibodies derived from HIV-1 patient sera pre-bound to 
Viruses 2014, 6 3741 
 
 
GammaBind Plus Sepharose (GE Healthcare, Little Chalfont, United Kingdom). For detection of 
ubiquitinated Gag proteins directly by Western blotting cells were lysed with RIPA with 20 μM 
lactacystin and 20 μM carbobenzoxyl-leucine-leucine-leucinal and soluble extracts were analyzed by 
Western blotting. 
2.3. SDS PAGE and Western Blotting 
Protein samples were separated by SDS-PAGE [37] and subsequently transferred onto PVDF  
membranes (GE Healthcare). Membranes were blocked with 3% bovine serum albumin and incubated 
with the appropriate primary antibody (Ab). HA-tagged ubiquitin was visualized using an HA-reactive 
monoclonal antibody (mAb) directly conjugated to horse radish peroxidase (HRP) (Roche, Basel, 
Switzerland). FLAG-ALIX was detected by an anti-FLAG mAb directly conjugated to HRP (Sigma, 
St. Louis, MO,USA). Gag was detected by a rabbit Ab recognizing p24 (Seramun, Heidesee, 
Germany). The anti-mouse and anti-rabbit secondary antibodies coupled to HRP were obtained from 
Dianova (Dianova, Hamburg, Germany). Protein bands were quantified using AIDA (Raytest, 
Straubenhardt. Germany). For the linkage specific staining of polyubiquitin the rabbit mAb Apu2 
(Millipore, Darmstadt, Germany) was used for the detection of K48-linked polyubiquitin and the mouse 
mAb HWA4C4 (Enzo, Farmingdale, NY, USA) for K63-linked polyubiquitin. Recombinant 
polyubiquitin chains either linked via the internal lysine 48 or 63 (Boston Biochem, Cambridge, MA, 
USA) served as specificity control. The mouse anti-Transferrin receptor antibody was purchased from 
Life Technologies and the anti-β-actin antibody from Sigma. 
2.4. Expression Plasmids 
The plasmid for expression of hemagglutinin (HA)-tagged ubiquitin (HA-Ub) was kindly provided 
by H.-G. Kräusslich and is described elsewhere [38]. The FLAG-ALIX expression construct is 
described elsewhere [39]. The NL4-3 [40] derived expression constructs pNLenv1 [41] and p∆R [38] 
harboring the S40F and ∆PTAP mutations have been previously described [30], the S40F/∆PTAP 
double mutant has been established analogously. All point mutations were introduced by site-directed 
mutagenesis (QuikChange
®
 Lightning, Life Technologies) using a pair of complementary primers 
(only forward primers are annotated). Mutational inactivation of the viral protease (PR
−
) was carried 
out using the primer pair 5’-gga agc tct att agc tac agg agc aga tga-3’. Alternatively Ritonavir was 
added to a final concentration of 10 μM 4 h post transfection to inhibit Gag processing. The S40D 
mutation was introduced by using the primer pair 5’-act gta tcc ttt agc cga cct cag atc act ctt-3’, the 
S40N mutation using the primer pair 5’-act gta tcc ttt agc caa cct cag atc act ctt-3’, and the N-ctrl 
construct using the primer pair 5’-act gta tcc ttt agc cag cct cag atc act ctt-3’. The MA G2A mutation 
was introduced by using the primer pair 5’-aga agg aga gag atg gct gcg aga gcg tcg gta-3’. The codon 
optimized Gag expression plasmids containing the SL sequence with wt p6 sequence and exchange of 
the two PTAP motifs have been described elsewhere [42,43]. Introduction of the S40F mutation in the 
syngag background was achieved by site-directed mutagenesis using the primer pair 5’-ctg tac ccc ctg 
acc ttc ctg agg agc ctg ttc ggc-3’, the S40A mutation by using the primer pair 5’-ctg tac ccc ctg acc gcc 
ctg agg agc ctg ttc ggc-3’, and the Y36A mutation with the primer pair 5’-cga caa gga gct ggc ccc cct 
gac c-3’. 
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2.5. Flow Cytometry 
For detection of H2-K
b
-bound SL-epitope, cells were stained with the allophycocyanin  
(APC)-conjugated 25D1.16 mAb (eBioscience, San Diego, CA, USA) diluted 1:100 in FACS buffer 
(5% [v/v] FCS, 0.02% [v/v] NaN3 in PBS). For detection of total H2-K
b
 molecules, cells were 
incubated with hybridoma cell culture supernatant containing the mAb B8-24-3 [44], followed by 
staining with secondary Alexa 647-conjugated anti-mouse Ab (Life Technologies). For intracellular 
Gag staining, cells were permeabilized using Cytofix/Cytoperm (BD Bioscience, San Jose, CA, USA). 
Gag was detected by staining with a FITC-conjugated anti-p24 Ab (KC57; Beckman Coulter, Brea, CA, 
USA) diluted 1:100 in Perm/Wash buffer (BD Bioscience). Flow cytometry was performed on a 
FACSCalibur using CellQuest software (BD Bioscience). Data were analyzed by using the FACS 
Express V3 software [45]. 





 hybridoma T cells B3Z express the lacZ reporter gene under 
the control of the NFAT enhancer [46]. HeLa-K
b
 cells transfected with syngag plasmids coding for 
Gag wt, Gag-SL wt, ∆PTAP-SL, S40F-SL, or S40F/∆PTAP-SL were detached and seeded in triplicates 
into 96 well plates, in concentrations ranging from 50,000 to 150 cells/well. After overnight coculture 
with 50,000 of B3Z cells in a total volume of 200 μL/well, cells were washed twice with PBS, lysed by 
addition of 100 μL of 0.15 mM chlorophenyl red β-galactopyranoside (CPRG), 0.5% NP-40 in PBS 
and the absorbance at 595 nm was determined in a plate reader (BioTek Instruments, Bad Friedrichs-
hall, Germany). 
2.7. Membrane Flotation 
The protocol for membrane flotation was adapted from [26]. Briefly, HeLa cells were extensively 
washed and scraped in homogenization buffer (0.25 M sucrose, 1 mM EDTA, 20 mM Tris HCl pH 
8.0) and lysed by sonication. The post-nuclear supernatant was adjusted to 40% OptiPrep and 
underlayed to 28% and 2.5% OptiPrep. Samples were centrifuged at 109,000 × g for 3 h. Five fractions 
were collected from the top of the gradient and subsequently analyzed by Western blotting. 
2.8. Peptide Synthesis 
Synthesis and purification of synthetic p6 fragments, p6(23-52)S40F, p6(23-52)S40N and  
p6(23-52)S40D were performed as described in detail elsewhere [47,48]. 
2.9. Preparation of Samples for NMR Spectroscopy 
The peptides were dissolved without pH adjustment (pH ~ 3.0) to final concentrations of 1–2 mM 
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2.10. NMR Spectroscopy 
Two-dimensional (2D) 
1
H correlation spectroscopy (COSY), total correlation spectroscopy 
(TOCSY) and NOESY NMR spectra of the C-terminal p6 peptides were recorded without spinning at 
300 K on a Bruker Avance 600 MHz instrument equipped with an UltraShield
TM
 Plus magnet and a 
triple resonance cryo-probe head with gradient unit. Data acquisition, processing and spectral analysis 
were in all cases performed with standard Bruker software [49]. All spectra were internally referenced 
to the residual TFE-DH signal at 3.95 ppm. The applied mixing times for the TOCSY and NOESY 
experiments were in all instances 110 ms and 250 ms, respectively. The unambiguous amino acid spin 
systems and the sequential assignments were established using a standard procedure [50] combining 
homonuclear 2D 
1
H TOCSY and 2D 
1
H NOESY NMR spectral data. Individual spin systems were 
identified from 2D 
1
H TOCSY spectra, starting from the backbone amide protons and sequence-
specific assignments were determined from cross-peaks in the 2D 
1
H NOESY spectra based on short 






Hβ nuclei of amino acid residue i and 
1
HN of residue i + 1. 
This procedure provided the unambiguous assignments of all the spin systems for each of the mutant 
C-terminal p6 peptides (Tables S1-S3) and allowed a direct comparison with the data for the wt  
peptide reported previously under the same solution conditions [48]. 
2.11. Structural Calculations 
The crosspeaks observed in the 2D 
1
H NOESY spectrum of p6(23-52)S40F were assigned and  
integrated using Sparky NMR Analysis version 3.1.1.4 [51]. Distances were derived from NOE peak 
volumes in the 
1
H NOESY spectrum and structure calculations were performed by using CYANA 2.1 
[52]. The NHi - NHi+1, NHi - NHi+2, αHi - NHi+2, αHi - NHi+3, αHi - NHi+4 and αHi - βHi +3 crosspeaks 
observed in the NOESY spectrum were used for structure calculation. 100 structures were calculated. 
The calculated structures were processed and aligned with PyMOL software [53]. The residues I31-
D48, which are included in the C-terminal helix of p6, were chosen as fitting regions for alignment of 
the 20 best structures (Figure S1). 
3. Results 
3.1. Mutation of Ser-40 Elevates Gag Ubiquitination 
Recently, we and others reported that specific mutation of the highly conserved serine 40 to  
phenylalanine (S40F) within p6 leads to impaired CA-SP1 processing resulting in an abnormal core 
morphology and thus in a reduced replication capacity, whereas virus release and binding of ALIX to 
p6 were not reduced [30,31]. Later, it was reported by others that this S40F mutation induces 
filopodia-like membrane protrusions harboring Gag [31]. However, the mechanism by which mutation 
of Ser-40 in p6 affects CA-SP1 processing, virus morphology, and filopodia formation remained  
completely unclear. It has been shown that Ser-40 is phosphorylated in the context of the Gag 
precursor Pr55 by aPKC and that about overall 5-10% of the mature p6 protein is phosphorylated in 
virus particles [27,28,54]. Since phosphorylation is known to trigger ubiquitination [35], we 
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investigated whether Ser-40 affects this modification of Gag, which was previously shown to be 
dependent only on the integrity of the PTAP L-domain [26,38,55]. 
Western blot analyses of HeLa cell lysates derived from cells transfected with the subgenomic HIV-1 
expression construct pNLenv1 [41] directing the expression of wt and the S40F mutant reveal a ladder 
of bands migrating above Pr55 for the S40F mutant, which are reminiscent of ubiquitinated Gag 
species (Figure 1A). The same analyses of virus like particle (VLP) preparations displayed a very 
similar pattern of high molecular weight species of Gag for the S40F but not for the wt VLPs (Figure 
1B). Quantification of the amount of CA in the VLP fraction versus the total amount of Gag confirmed 
the previously reported wild type efficiency for virus release of the S40F mutant (Figure 1C) [30,31]. 
Enhanced Gag ubiquitination in the context of normal virus release and intact L-domain functions is 
unprecedented, as increased Gag ubiquitination until now has only been described for L-domain 
mutants of HIV-1 [26,38,55]. The previously reported CA-SP1 processing defect of the S40F mutant 
[30,31] is visible upon shorter exposure of the Western blot membrane (Figure 1A,B, lower panels). 
 
Figure 1. The S40F mutation in p6 augments Gag ubiquitination. HeLa cells were 
transfected with the env-deleted HIV-1 expression plasmid pNLenv1, as wt or S40F 
mutant, and lysed under conditions where the 26S proteasome and ubiquitin hydrolases 
were inhibited. Cell lysates (A) and VLP fractions (B) were analyzed by Western blotting 
using a CA-reactive antiserum. Shorter exposures of the Western blots revealing the delay 
in CA processing for the S40F mutant are depicted in the lower panels (C). The VLP 
release was quantified by calculating the amount of CA in the VLP fraction versus the 
amount of total Gag detected in cells and VLPs. Bars represent mean values of seven 
independent experiments ± SD. Values on the y-axis were adjusted that wt matches 100%. 
To confirm that this ladder of higher molecular weight species indeed represents ubiquitinated Gag 
proteins, HeLa cells were co-transfected with Gag expression constructs and a plasmid encoding  
HA-tagged ubiquitin (HA-Ub). As control, we included the ∆PTAP L-domain mutant where the 
tetrapeptide motif PTAP is replaced by LIRL [10,56], a mutant which was previously shown to exhibit 
high levels of Gag ubiquitination in cells [26,38,55]. As Watanabe et al. observed the formation of 
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employed a PR-deficient subgenomic HIV-1 expression construct that harbors an inactive RT and a 
primer binding site deletion (p∆R PR− [38]). Additionally, by this approach we wanted to ensure 
comparable levels of Pr55 polyprotein as the substrate for ubiquitination, because the ∆PTAP mutation 
causes a Gag processing defect leading to accumulation of cell associated Pr55, a phenotype which is 
not observed for the S40F mutant, which shows wt Gag processing except for the CA-SP1 cleavage 
(Figure 1B). Gag was precipitated from whole cell lysates with antibodies derived from pooled HIV-1 
patient sera. Ubiquitinated Gag was specifically detected by Western blotting using an HA-reactive 
antibody. Results shown in Figure 2A confirm that the ladder observed for the S40F mutant consists of 
ubiquitinated Gag species and that this modification occurs to a similar extent as for the ∆PTAP 
mutant. 
 
Figure 2. The S40F mediated ubiquitination of Gag occurs irrespective of Gag processing 
or other viral proteins. HeLa cells were co-transfected with HA-ubiquitin and either p∆R 
PR
−
 plasmids (A) or syngag plasmids encoding for either wt Gag, or the p6 mutant S40F or 
∆PTAP, respectively (B). Gag was recovered by immunoprecipitation from denatured 
whole cell lysates with anti-HIV antibodies, and ubiquitinated Gag molecules were 
subsequently visualized by Western blot using antibodies specific for HA. The amount of 
Gag recovered by immune precipitation, as well as Gag recovered from whole cell lysates 
was detected with CA specific antibodies; (C) Evaluation of three or five independently 
performed experiments for the p∆R or the syngag system, respectively. Values were 
matched to the ubiquitin signal of the ∆PTAP mutant (100%) and represent the arithmetic 
mean ± SD. 
It was suggested by Watanabe et al. that Gag alone is sufficient for the formation of S40F-induced 
filopodia [31]. To investigate whether the S40F mediated Gag ubiquitination occurs independently of 
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synthetic gag gene expressed from a CMV promoter driven expression plasmid (psyngag) [42,57]. 
Introduction of the S40F mutation into the psyngag background enhances the Gag ubiquitination at  
a similar rate when compared to the situation when Gag was expressed in the context of the HIV-1 
genome (Figure 2B). Again, the level of Gag ubiquitination for the S40F mutant was almost 
indistinguishable from that observed for the ∆PTAP mutant. As in this experimental setting the 
turnover of polyubiquitinated Gag by either the 26S proteasome or deubiquitinating enzymes is 
prevented, also the formation of ubiquitinated Gag species was observed in the wt situation, although 
at much lower level, approximately 10%–20% of the Gag-ubiquitin adducts detected for S40F and 
∆PTAP as measured by densitometry (Figure 2C). 
Therefore, the S40F mutant exhibits Gag ubiquitination independently of Gag processing or other 
HIV-1 proteins, and this ubiquitination occurs to an extent in cell and VLP fraction that is comparable 
to that of the ∆PTAP mutant. 
3.2. The Non-Conservative Amino Acid Exchange S40F, but Not the Conservative Substitutions S40D 
or S40N, Induces Elevated Gag Ubiquitination 
It has been shown that p6, as a substrate for several virus associated kinases, is the predominant 
phosphoprotein in virus particles [27]. However, it has only been demonstrated that the 
phosphorylation of Thr-23 by Erk-2 is important for budding and maturation of virus particles [29], 
whereas the aPKC mediated phosphorylation of Ser-40 facilitates Vpr incorporation [28]. 
Based on our observation (Figures 1 and 2), it was intriguing to speculate that phosphorylation of 
Ser-40 by aPKC might trigger, or at least somehow regulate, the ubiquitination of Gag, yet the 
hydrophobic Phe cannot mimic at all a phosphoseryl residue. To more directly analyze a potential 
correlation between phosphorylation and ubiquitination, we established an S40D mutant in the context 
of the HIV-1 NL4-3 proviral clone [40]. The negative charge of the aspartic acid should function as 
phosphomimetic and thus simulate a constitutively phosphorylated serine in position 40. Additionally, 
we included an S40N mutant as a more conservative exchange for a phosphoseryl residue, which was 
also chosen by Radestock et al. in previous functional studies on p6 phosphorylation [54]. Since  
Ser-40 in p6 can only be exchanged to Phe without disturbing the amino acid sequence encoded by the 
overlapping pol-ORF [30], the p6 S40N mutation results in a Phe to Gln exchange in position 56 in the 
Pol-protein. As control, this mutation in Pol was established in the NL4-3 background while leaving 
the p6 amino acid sequence unchanged (N-ctrl). However, in case of the S40D mutant the resulting 
Phe to Arg mutation in position 56 in the Pol-protein could not be introduced in the context of the wt 
p6 sequence due to constraints of the codon usage and the overlapping ORFs. As particularly Ser-40 in 
p6 overlaps with the cleavage site between the transframe p6* protein and PR in the pol-ORF, we 
expected that the exchanges in the pol-ORF might interfere with the PR activity. To circumvent this 
potential problem, we applied the PR-inhibitor Ritonavir to yield comparable amounts of Pr55. 
However, analyses of the cell-associated Gag ubiquitination revealed that none of the conservative 
mutants, S40N or S40D, can increase Gag ubiquitination as it was observed for the S40F mutant 
(Figure 3A). In addition, also the N-ctrl mutant exhibits wt Gag ubiquitination (Figure 3A) indicating 
that the phenomenon is not related to changes in the overlapping pol-ORF. Our suspicion that this 
phenomenon is somehow specific for S40F, was further supported by recent finding from Watanabe et 
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al., demonstrating that the S40A mutant displays wt CA-SP1 processing [31]. In consistency, Western 
blot analyses revealed that the S40A mutation had, as for the S40N and S40D mutations, no obvious 
impact on ubiquitination of Gag (Figure 3B). Moreover, comparable amounts of Gag were detected 
intra- and extracellularly (cell and VLP fraction, Figure 3A,B, lower panels), revealing no decrease in 
virus release. 
Thus, we conclude that the enhanced Gag ubiquitination of the S40F mutant, like the formation of 
the filopodia-like structures and the defective CA-SP1 processing, represents most probably a Phe  
specific phenomenon. 
 
Figure 3. Influence of the S40N, S40D or S40A mutation on Gag ubiquitination.  
(A) HeLa cells were co-transfected with HA-tagged ubiquitin and pNL4-3 plasmids,  
as indicated. Gag processing was inhibited by the addition of the PR-inhibitor Ritonavir.  
The isolation and detection of ubiquitinated Gag species from cell fractions were carried 
out as described in Figure 2. The amount of Gag recovered by either immune precipitation 
or from whole cell lysates, and the VLP fraction was detected with CA specific antibodies;  
(B) HeLa cells were co-transfected with HA-tagged ubiquitin and the syngag expression 
plasmids directing the expression of wt Gag and mutants thereof. The isolation and 
detection of ubiquitinated Gag species from cell fractions were carried out as described in 
Figure 2. The amount of Gag recovered by immune precipitation, Gag recovered from 
whole cell lysate, and the VLP fraction was detected with CA specific antibodies. 
3.3. The S40F Mutation Increases the Amount of Membrane Associated Gag 
First in vitro evidence that in HIV-1 expressing cells the introduction of the S40F mutation 
somehow increases the amount of Pr55 in membrane associated assembly compartments was reported 
previously [58]. Therefore an enhanced membrane localization of Gag could possibly account for its 
elevated levels of ubiquitination according to the model for ubiquitination of ∆PTAP mutants by 
membrane resident ubiquitin ligases [26]. 
Thus, we investigated the impact of the S40F mutation on the intracellular distribution of Gag in  
PR-deficient context by membrane flotation, an established method that has been previously applied to 
address the membrane binding properties of Gag mutants [26,38,59]. The amount of Gag in each 
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abrogates the myristoylation of Gag, and, thus, strongly decreases membrane binding [60], and the 
∆PTAP mutant, which was shown previously to exhibit increased amounts of membrane bound Gag 
[26]. Detection of transferrin receptor and β-actin by Western blotting revealed a complete separation of 
both marker proteins and identified fractions 1 and 2 as the membrane-containing fractions and 
fractions 4 and 5 as cytosolic fraction (Figure 4A). 
 
Figure 4. The S40F mutation increases selectively the membrane association of Pr55.  
(A) HeLa cells were transfected with p∆R PR− HIV-1 constructs directing the expression 
of either wt Gag, the p6 S40F, S40N, S40D or ∆PTAP mutants or the MA G2A mutant.  
The cells were lysed by sonication and the post-nuclear supernatant (PNS) was subjected to 
membrane flotation. Fractions were collected and analyzed by Western blotting for Gag.  
The Western blot membrane was reprobed with antibodies specific for transferrin receptor 
(TfR) and β-actin as marker proteins for the membrane or cytosolic fractions, respectively. 
One representative example of TfR and β-actin blots is shown; (B) Band intensities of the 
Gag blots were densitometrically quantified and the distribution of Gag was determined for 
each mutant; (C) The ratio of Gag detected in the membrane fractions (fractions 1 and 2) 
versus the cytosolic fraction (fractions 4 and 5) was calculated. Values represent the mean 
of 4 independent experiments ± SD, and were adjusted that wt matches 1. 
In consistency with previously reported surface plasmon resonance analyses [58], only the mutant 
S40F, but none of the conservative mutations S40D and S40N, increases the membrane associtation of 
Gag when compared to wt (Figure 4A). Quantification of the band intensities revealed that the S40F 
mutant exhibits a distribution of Gag within the gradient which is comparable to that of the ∆PTAP 
mutant (Figure 4B). Calculation of the ratio between membrane (fractions 1 and 2) and cytoplasmic 
(fraction 4) Gag from four independent experiments revealed a significant 1.75-fold increase of 
membrane associated Gag for the S40F mutant when compared to wt protein or the S40D and S40N 
mutants (Figure 4C). 
Altogether, these data demonstrate that the S40F mutant enhances the membrane association of Gag 
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wt-like virus release. Thus, CA-SP1 processing, virus maturation, membrane interaction, and Gag  
ubiquitination appear to be connected to each other, inasmuch as only the S40F, but none of the  
investigated conservative mutations, influence those processes. 
3.4. Augmentation of the VLP Release by ALIX Does Not Affect Gag Ubiquitination 
Next, we wanted to investigate the consequences of ALIX overexpression on Gag ubiquitination, 
which was demonstrated to restore virus release of PTAP-deficient Gag mutants while being inactive 
on release of the S40F mutant [12,13,30]. It was hypothesized previously that ubiquitination of Gag 
occurs primarily by plasma membrane resident ubiquitin ligases, particularly when Gag accumulates 
there in the case of ∆PTAP mutants [26,38,55]. Thus, in the reverse case, restoring virus release of a 
PTAP-deficient mutant by overexpressing ALIX should reduce Gag ubiquitination, a question that has 
not been addressed yet. Additionally, as an increased ALIX-binding has been implicated in the 
formation of the S40F-induced filopodia [31], we now speculate that ALIX overexpression might 
regulate this phenomenon by enhancing Gag ubiquitination. 
 
Figure 5. Overexpression of ALIX increases virus release but has no influence on Gag  
ubiquitination. (A) HeLa cells were co-transfected with HA-tagged ubiquitin, pR constructs 
as indicated, and either with, or without, FLAG-ALIX plasmid. Gag processing was  
inhibited by the addition of the PR-inhibitor Ritonavir. For detection of ubiquitinated Gag 
species, Gag was precipitated from whole cell lysates by immunoprecipitation using  
anti-HIV antibodies, and ubiquitin was detected by anti-HA staining. VLPs were pelleted 
from the supernatant and the amount of Gag released as VLPs was detected by anti-CA 
staining; (B) Evaluation of three independently performed experiments. Bars represent the 
arithmetic mean ± SD. The numbering is according to (A). 
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In order to investigate whether or not there is any correlation between the efficiency of virus release 
or the increased ALIX binding and Gag ubiquitination, we co-transfected HeLa cells with p∆R wt,  
the S40F and ∆PTAP mutants, as well as a S40F/∆PTAP double mutant, with or without ALIX 
expression plasmids. Consistent with previous findings, ALIX overexpression efficiently restored the 
VLP release of the ∆PTAP and the S40F/∆PTAP mutants, whereas the wt and the S40F mutant were 
not affected (Figure 5A, compare lanes 4 with 5 and 8 with 9) [12,13,30]. Analyses of Gag 
ubiquitination levels in cells revealed that, although ALIX overexpression could significantly enhance 
virus release of the PTAP-deficient constructs, it had no effect on the ubiquitination of Gag in any of 
the cases investigated (Figure 5A). The statistical significance of this finding was further confirmed by 
quantification of the ubiquitin signals from three independent experiments (Figure 5B). All together, 
these results indicate that the level of Gag ubiquitination does not correlate with the efficiency of virus 
release, now also observed in the context of ∆PTAP mutants. This notion is further supported by the 
observation that the S40F mutant, which exhibits wt virus release efficiency, becomes ubiquitinated 
like the release-deficient ∆PTAP mutant (Figure 5). Moreover, the respective S40F/∆PTAP double 
mutant shows an about two-fold increase in ubiquitination compared to the respective single mutants 
which might even indicate an additive effect of the S40F and ∆PTAP mutations on Gag ubiquitination 
(Figure 5B). 
3.5. The S40F Mutation Increases the K48-Linked Polyubiquitination of Gag 
Previous studies reported that all major processing products of Gag can be modified by attachment 
of ubiquitin [21,22,25,26,38]. Particularly, monoubiquitination of lysine residues in the proximity to  
L-domains was demonstrated to increase the affinity of Gag to TSG101 in vitro [7]. Moreover, a recent 
study implicated a possible link between the S40F mutation and syntenin [31], a protein which was 
characterized to bind polyubiquitin irrespectively of the linkage type [33,34]. Furthermore, it was  
previously shown that mutation of the PTAP L-domain leads to a prolonged membrane association of 
Gag which subsequently induces its exposure to membrane resident ubiquitin ligases and, thus, 
elevates its K48-linked polyubiquitination [26,42]. 
Therefore, we wanted to investigate what kind of polyubiquitination is induced by the S40F 
mutation. We applied a system that discriminates between K48- and K63-linked polyubiquitination by 
using linkage-specific polyubiquitin antibodies. 
Due to the nature of ubiquitination at least some of the Gag-ubiquitin adducts might be inaccessible 
for the immunoprecipitation after de- and re-naturation of cell extracts. This disadvantage was 
circumvented by analyzing purified VLP preparations where all virion associated Gag-ubiquitin 
adducts become observable by Western blot. Analyses of wt, ∆PTAP or S40F VLPs using the K48-
specific antibody demonstrated that even the wt VLPs displays a very weak baseline amount of K48-
linked polyubiquitination, that was clearly enhanced when the PTAP or Ser-40 were mutated (Figure 
6A). In contrast, a negative result was observed when the Western blots of the VLP fractions were 
stained for K63-linked polyubiquitin, although the corresponding recombinant polyubiquitin chains 
were specifically recognized in the same Western blot and the sensitivity was comparable to the 
detection of K48-linked polyubiquitin (Figure 6B). 




Figure 6. Gag is modified by K48-linked polyubiquitin. HeLa cells were transfected with 
p∆R PR− plasmids encoding wt Gag, or mutants thereof as indicated. 48 h post transfection 
VLPs were pelleted from the cell culture supernatants through a 20% sucrose cushions and 
subsequently analyzed by Western blotting using antibodies specifically recognizing either 
K48- (A) or K63-linked (B) polyubiquitin. 100 ng of recombinant polyubiquitin chains 
linked either by internal lysine 48 or 63 were used as control (Ub3-7 K48 or Ub3-7 K63,  
respectively). Comparable amount of Gag was present in each VLP preparation as shown 
by staining with anti-CA antibodies (lower panels (A),(B)). 
These findings demonstrate that predominantly K48-linked polyubiquitin chains are attached to Gag 
and that this effect is enhanced when Ser-40 is mutated. The same phenomenon was previously 
described for the ∆PTAP mutant and characterized to depend on an increased membrane binding of 
Gag [26,42]. Furthermore, these results confirm that these K48-linked polyubiquitinated Gag species 
even participate in Gag assembly process for all variants, wt, ∆PTAP, S40F, though at different levels. 
3.6. The S40F Mutation Enhances MHC-I Antigen Presentation of Gag 
It is well established that the K48-linked polyubiquitination is a prerequisite for the entry of 
proteins into the MHC-I antigen presentation pathway [61]. To more precisely ensure our findings 
concerning the S40F mutant, we sought to use another read out system for the extent of K48-linked 
polyubiquitination which is the presentation of Gag derived epitopes in the context of MHC-I 
molecules at the cell surface. This immunochemical approach was previously proven as a highly 
reliable and sensitive method to follow the entry of Gag into the UPS [42,43,46,62]. As there are no 
antibodies available which recognize Gag-derived epitopes bound to MHC-I molecules, the 
ovalbumin-derived sequence SIINFEKL (SL) was introduced as a model epitope into the p2 spacer 
region of Gag (Gag-SL [43]). By using this method, elaborated previously for the ∆PTAP mutant [42], 
we wanted to investigate whether the S40F mutation, which clearly increases K48-linked 
polyubiquitination, also enhances the entry of Gag into the MHC-I pathway. 




, [63]) were transfected 
with expression plasmids coding for Gag-SL, ∆PTAP-SL, S40F-SL and S40F/∆PTAP-SL. Flow cytometry 
using the mAb 25D1.16, which specifically recognizes H2-K
b
-bound SL, revealed that cells expressing 
∆PTAP-SL or S40F-SL displayed higher numbers of H2-Kb-SL complexes at the cell surface when 
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mutant even revealed the strongest effect on SL presentation (Figure 7A). According to the rule of 
antigen presentation, the amount of intracellular antigen should directly correlate with the number of 
epitopes presented on the cell surface, provided that those antigens exhibit similar turnover rates [64]. 
In order to compensate for possible differences in the steady state levels of the Gag-SL variants, the 
mean fluorescence intensity (MFI) of the staining with 25D1.16 was normalized to the MFI of the 
intracellular staining for Gag. Even when the budding defect and, thus, the accumulation of cell 
associated Gag was taken into account, analyses of three independent experiments revealed an 
approximately threefold increase in SL-presentation when the ∆PTAP-SL or S40F-SL variant were 
compared to wt Gag-SL (Figure 7B). The S40F/∆PTAP-SL exhibits an even more pronounced, 
approximately fivefold increase in SL-presentation in comparison to wt Gag-SL. 
 
Figure 7. The S40F mutation induces an enhanced MHC-I antigen presentation of Gag 
derived epitopes. (A) HeLa-K
b
 cells were transfected with syngag expression constructs  
coding for Gag-SL, ΔPTAP-SL, S40F-SL and S40F/ΔPTAP-SL. H2-Kb-SL complexes  
presented on the surface of Gag-positive cells were quantified by flow cytometry using 
25D1.16-APC. A representative histogram plot is shown; (B) Quantification of three  
independent experiments. The mean fluorescence intensity (MFI) of the 25D1.16 staining 
was normalized to the MFI of the intracellular anti-Gag staining obtained after 
permeabilization of the plasma membrane. Bars represent mean values ± SD; (C) Analysis 
of the Gag ubiquitination of the corresponding constructs. Gag was recovered from whole 
cell lysates by immunoprecipitation using anti-HIV antibodies, and ubiquitinated species 
were detected by anti-HA staining; (D) Activation of B3Z hybridoma T cells was assessed 
by a colorimetric β-galactosidase assay after overnight cocultivation with HeLa-Kb cells 
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It was previously well elaborated that the quantification of SL loaded K
b
 molecules on the cell 
surface correlates with an even more sensitive method, the activation of B3Z hybridoma T cells [46].  
These indicator cells express a T-cell receptor which specifically recognizes SL bound to H2-K
b
, 
leading to T-cell activation and thus the induction of the lacZ gene expression. To investigate if the 
S40F mutation enhances the immunogenicity of Gag, we tested the ability of HeLa-K
b
 cells expressing  
Gag-SL wt, ∆PTAP-SL, S40F-SL or S40F/∆PTAP-SL to activate B3Z hybridoma T cells. As a 
negative control, HeLa-K
b
 cells were transfected with Gag wt without SL. After overnight 
cocultivation, β-galactosidase activity was measured by a colorimetric assay, showing that cells 
expressing ΔPTAP-SL or S40F-SL mutant were able to induce a clearly enhanced T-cell activation 
over a broad range of effector-to-target ratios when compared to cells expressing wt Gag-SL (Figure 
7D). In correlation with the analysis of the Gag ubiquitination by Western blot (Figure 7C) and the 
MHC-I antigen presentation (Figure 7A,B), the S40F/∆PTAP-SL mutant displayed the highest 
potential to activate T cells in vitro. 
Thus, these sensitive immunological methods underline that both, PTAP deletion and mutation of 
Ser-40 with Phe, act independently of each other, but can also exert an additive effect on the K48-
linked polyubiquitination of Gag and, consequently, on its entry into the UPS. 
3.7. Mutations of Ser-40 Do Not Change the Extent or Localization of Secondary Structure of p6 
S40F, but none of the conservative exchanges, induces the phenotype described above. In order to 
unravel the underlying molecular rationale, we set out to investigate potential structural consequences 
of the mutations of Ser-40 of p6 by NMR spectroscopy. In order to achieve structural information at 
atomic resolution, chemical shift index (CSI) plots were created of the individual 
1
H resonances of 
each p6 peptide. CSI plots of the α-protons (Hα) chemical shifts relative to those of residues in a 
random coil have proved to be an appropriate and powerful method for determining the presence of 
secondary structure in peptides and proteins [50,65]. It has been shown experimentally that Hα-proton 
chemical shifts greater than 0.1 ppm relative to the random coil values are qualitative indicators of 
secondary structure [65]. A minimum of four adjacent residues with an upfield shift relative to random 
coil (negative CSI) is indicative of an α-helix, whereas β-sheets require a minimum of three residues 
with downfield shifts (positive CSI) [65]. 
To ascertain whether the S40F, S40N or S40D mutations alter the C-terminal helix of p6, the 
synthetic peptides (s)p6(23-52)S40F, (s)p6(23-52)S40D and (s)p6(23-52)S40N were characterised by 
1
H NMR spectroscopy. Previously, we solved the structure of the wt peptide sp6(23-52) by NMR and 
found that the C-terminal fragment adopts the same structure as the full length wt molecule sp6(1-52) 
[48]. Therefore, it was legitimate to analyze the structure of the C-terminal mutant peptides and 
compare it with the wt molecule. 
After complete assignment of the 
1
H resonances of the NMR spectra of each peptide, NOE cross 
peaks important for secondary structure identification, were determined. The observation of NHi - 
NHi+1, NHi - NHi+2, αHi - NHi+2, αHi - NHi+3, αHi - NHi+4 and αHi - βHi+3 NOEs, which are indicative 
of helical secondary structure, showed that, similarly to wt sp6(23-52), the mutant sp6(23-52)S40F has a 
preference for an α-helical structure involving residues Ile-31 to Asp-48 under hydrophobic 
membranous conditions (50% aqueous trifluorethanol (TFE) solution) [30]. Substitution of Ser-40 with 
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Phe did not change the position or number of residues included in the C-terminal helix compared with 
wt sp6(23-52), and their structures appear to be even similar. This was confirmed by a comparison of 
plots of the α-proton chemical shifts relative to those of random coil values (Figure 8), which indicates 
that the substitution of Ser-40 with Phe slightly stabilizes the region of the C-terminal helix comprised 
of residues Leu-41 to Leu-44, proximal to Phe-40. The conservative mutations S40D and S40N did not 
provide any observable effect on the secondary structure, which like the S40F mutation, resemble that of 
wt sp6(23-52) (Figure 8). 
 
Figure 8. Mutations of Ser-40 do not change the extent or position of the secondary 
structure of the C-terminus of p6. Chemical shift differences (ppm) of the α-protons 
between the experimental values and those for residues in a random coil for the C-terminal 
peptides sp6(23-52) wt and the mutants sp6(23-52)S40F, sp6(23-52)S40D and sp6(23-
52)S40N in 50% aqueous TFE at pH 3. 
3.8. The S40F Mutation Creates a Hydrophobic Domain Involving Aromatic Residues Tyr-36 and  
Phe-40 at the Same Surface of the C-Terminal Helix of p6 
To rationalize the increased membrane association caused by the S40F mutation, the structure of 
sp6(23-52)S40F was calculated based on the assigned crosspeaks observed in the 2D 
1
H NOESY  
spectrum. The NMR structure revealed that the residue at position 40 is located at the same surface of 
the helix (separated by one turn of the helix), and, thus, is in spatial proximity to the bulky 
hydrophobic residue Tyr-36 (Figure 9A). Thus, the S40F mutation creates a hydrophobic domain 
involving the bulky aromatic residues Tyr-36 and Phe-40, which may account for the observed 
increased membrane affinity of the S40F mutant. This indicates that the C-terminal α-helix of p6 
sp623-52wt
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characterized by NMR spectroscopy should be also present and functionally active in HIV-1 
expressing cells. 
 
Figure 9. NMR structure of p6(23-52)S40F confirms formation of a new hydrophobic  
domain. (A) Structure of sp6(23-52)S40F determined by NMR spectroscopy. The residues 
Y36 and F40, which are located at the same surface of the helix, forming a new 
hydrophobic domain within the C-terminal helix of p6, are labeled in orange. (B) HeLa 
cells were co-transfected with HA-tagged ubiquitin and the syngag expression plasmids 
directing the expression of wt Gag and mutants thereof. The isolation and detection of 
ubiquitinated Gag species from cell fractions were carried out as described in Figure 2B. 
The amount of Gag recovered by immune precipitation and Gag recovered from whole cell 
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To confirm that the Tyr-36 plays a crucial role in the formation of the hydrophobic patch in  
Gag-expressing cells, we examined the Gag ubiquitination of the Y36A mutant, carrying an exchange 
in position 36 from Tyr to Ala, and the Y36A/S40F double mutant (Figure 9B). Western blot analyses 
revealed that the Y36A mutant alone reveals no impact on the Gag ubiquitination when compared to 
wt Gag. However, in the context of the Y36A/S40F double mutant, the Y36A mutation reverts the  
ubiquitination phenotype induced by the S40F mutation. Consistently with the NMR structural data 
(Figure 9A), Tyr-36 represents an integral component of this newly formed hydrophobic patch at the  
C-terminus of p6 which appears to be required for membrane interaction and ubiquitination of Gag. 
4. Discussion 
In the present study we characterize a potential membrane interacting domain, at least for the 
natural occurring p6 mutant S40F, which is induced by the formation of a hydrophobic patch involving 
Phe-40 and Tyr-36 within the C-terminal α-helix of p6. This altered membrane association 
subsequently induces K48-linked polyubiquitination of Gag, without affecting virus release. 
It is commonly accepted that ubiquitin plays an important role in retrovirus release, though its 
precise function in this process remains elusive so far. High amount of free ubiquitin was found in 
HIV-1, simian immunodeficiency virus (SIV), murine leukemia virus (MuLV) and avian leukosis virus 
(ALV) particles [21,22,66]. In addition, ubiquitinated species of Gag have been reported for HIV-1, 
SIV, and MuLV [21,22,38]. Moreover, in the case of equine infectious anemia virus (EIAV) and 
prototypic foamy virus (PFV), a stable C-terminal ubiquitin fusion to Gag can function as a signal for 
ESCRT-recruitment in the absence of an endogenous L-domain [67–69]. 
Early acting ESCRT factors like ESCRT-I, ESCRT-II, and ALIX possess ubiquitin binding 
domains, and thus, ubiquitin may play an important role in their substrate recognition [20,67,70,71]. Most 
characterized ESCRT substrates at endosomes become monoubiquitinated [18,72,73] or K63-
polyubiquitinated [74,75]. Thus, ubiquitination of Gag is believed to be beneficial to the budding 
process by enhancing its affinity to the ESCRT [7]. Additionally, the attachment of K63-linked 
polyubiquitin chains was detected in released particles derived from an artificial minimal Gag construct, 
and therefore is thought to be involved in HIV-1 budding, yet their presence in HIV-1 particles still 
remains to be demonstrated [76,77]. 
In case of HIV-1, it was hypothesized that assembling Gag is likely recognized by membrane 
resident ubiquitin ligases, and this ubiquitination of Gag in turn was proposed to cooperate with L-
domains to efficiently mediate virus release by the ESCRT complex [7,26,55,78]. Based on that, it was 
also assumed that the prolonged membrane association, caused by impaired L-domain function, 
subsequently leads to an increased exposure to ubiquitin ligases and thus results in an elevated 
ubiquitination of Gag [26]. 
We now show that the membrane interaction of Gag is specifically enhanced when Ser-40 of p6 is 
mutated to Phe. This enhancement strictly depends on the co-existence of residues Tyr-36 and Phe-40, 
which are both sufficient and necessary for the formation of a hydrophobic patch within the C-terminal 
α-helix of p6. Furthermore, in membranous environments p6 predominantly adopts α-helical structure 
which is the prerequisite for the formation of this hydrophobic patch [48,58]. However, while in the 
context of the S40F mutation, p6 likely contributes to membrane binding, this effect may not occur in 
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the context of wt Gag as in the absence of S40F the size of the hydrophobic patch might be too small to 
be able to contribute to membrane association. Nevertheless, an increased membrane association of 
Gag could at least provide one explanation for the augmented K48-linked polyubiquitination observed 
for the S40F mutant. 
It has been previously supposed by Salgado et al. that the hydrophobic C-terminal α-helix of p6  
inserts in plane into the lipid bilayer [36] and may, therefore, act as membrane targeting domain of 
Pr55, in addition to MA. This would drive at least a fraction of p6 molecules in the context of Pr55 to 
fold back to the membrane, a process which might even occur during assembly and consequently 
function as a secondary membrane binding domain of Gag (Figure 10). Most intriguingly, it has 
already been described that during assembly RNA associated Gag switches from a “compact” 
conformation to a final “stretched” conformation [79–81]. It would be intriguing to investigate the 
contribution of the S40F mutation to this process. In the compact conformation of Gag, NC is located 
in close proximity to MA, allowing both domains to interact with the inner leaflet of the plasma 
membrane by electrostatic interactions [81]. Thus, it is conceivable that in this dynamic process p6 
interacts with the lipid bilayer and might also participate in the structural transition of Gag. 
 
Figure 10. Model of the membrane interaction of Gag mediated by MA and the C-terminal 
α-helix of p6. 
The membrane interaction of p6 is specifically enhanced when Ser-40 is exchanged to Phe which 
can be rationalized from the NMR structure of p6 showing that the residue at position 40 is in spatial  
proximity to the bulky hydrophobic residue Tyr-36 (Figure 9). In general, an α-helix turns 100 degrees 
for each residue included. That means that formally 3.6 residues are required for a full turn of the helix 
[82]. Subsequently, amino acids 3-4 residues apart are relatively close in space and at the same surface 
of the α-helix. Thus, when the polar residue Ser-40 is replaced by the bulky non-polar Phe residue, a 
new hydrophobic domain is formed within the C-terminal helix of p6. The residue at position 40 is 
relatively close in space to Tyr-36, which then creates the new hydrophobic domain as the driving 
force that augments membrane interaction observed selectively for the S40F mutant. When the polar 
residue Ser-40 is substituted with either Asn or Asp, as exemplified by the mutants S40N and S40D, it 
is replaced with another polar, or even a negatively charged residue at this position. Thus, the 
hydrophobic domain, stretching up to Tyr-36, cannot be formed by these mutants. The fact that 
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p6 leads to increased membrane interaction is in agreement with the findings of Dathe et al. who 
reported hydrophobic domains as a determinant for membrane interaction of α-helical peptides [83]. 
We could neither detect an accumulation of budding virions on the cell surface nor a delay in virus 
release kinetics in our previous studies for the S40F mutant, which was then confirmed by  
Watanabe et al. [30,31]. Thus, it is legitimate to assume that this increase in membrane bound Gag 
observed for the S40F mutant occurs independently of virus release. Nevertheless, the budding 
competent S40F mutant, like the release defective ∆PTAP mutant, exhibits K48-linked 
polyubiquitination, a type of polyubiquitin chain that was never implicated in any ESCRT function. 
This, among other findings, indicates a role of ubiquitin and p6 distinct from promoting virus release 
[42]. Moreover, in the case of the S40F mutant Gag ubiquitination does not correlate with virus release 
and occurs independently of L-domain function. Thus, this type of ubiquitination might even originate 
from an ESCRT independent mechanism. This notion is further supported by the finding that 
overexpression of ALIX has no influence on Gag ubiquitination or virus release of the S40F mutant 
although it significantly enhances virus release of both the ∆PTAP mutant and the S40F/∆PTAP 
double mutant. In this particular case, ALIX might augment the release of Gag after its accumulation 
and subsequent ubiquitination at the plasma membrane. 
We failed to detect K63-linked polyubiquitinated Gag in purified virions. Given that such Gag 
species might still exist intracellularly, those could be either hydrolyzed during the budding process by 
ESCRT associated ubiquitin hydrolases like AMSH, which preferentially cleaves off K63-linked 
polyubiquitin [84], or just be excluded from virus assembly. 
Instead, we could demonstrate that virus-associated Gag is predominantly modified by K48-linked 
polyubiquitin, an effect which, however, was additionally enhanced when the PTAP motif or Ser-40 
were mutated. The K48-linked polyubiquitination of proteins is the prerequisite for their proteasomal 
degradation [61]. Although the steady state amount of S40F mutant Gag was not affected, the MHC-I 
antigen presentation, as the final consequence of proteasomal degradation, was significantly enhanced. 
This finding is consistent with earlier studies where an enhanced MHC-I antigen presentation did not 
correlate with a diminished half life of Gag [42,43]. A possible explanation for this phenomenon might 
be that just a minor fraction of Gag enters the UPS without reducing the overall level of Gag that 
remains not ubiquitinated. In consistency with this hypothesis is the notion that only a fraction of de 
novo synthesized proteins, approximately 5% to 10% depending on conditions and cell type, are 
entering the defective ribosomal product (DRiP) pathway [85]. In correlation with an enhanced MHC-I 
antigen presentation of Gag-derived epitopes, the S40F mutant displayed an increased capacity to 
activate T cells in vitro. This result implicates that S40F mutant Gag might have the potential to elicit a 
more potent activation of cytotoxic T-cells in vivo. 
One possible explanation for the proteasomal degradation of S40F mutant Gag would be misfolding 
induced by this non-conservative amino acid exchange. However, structural analysis of the C-terminal 
p6 mutant peptides by NMR revealed that these mutations do not induce any changes of the secondary 
structure of the protein, which in each instance is similar to that of the wt protein (Figure 8). Thus, we 
can exclude the possibility for any misfolding of p6 caused by the mutations of Ser-40 with Phe, Asn, 
or Asp. Hence, it is unlikely that the increased ubiquitination of HIV-Gag observed for the S40F 
mutant could be consequent to any potential misfolding within that domain of p6. 
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In addition to increasing the rate of proteasomal degradation, these K48-polyubiquitinated Gag 
molecules participate in the assembly of Gag and are efficiently incorporated into virus particles with 
still undefined consequences. This most probably indicates that the ubiquitination of Gag represents a 
late event in the budding process enabling a certain fraction of these Gag molecules to escape 
proteasomal degradation. Moreover, polyubiquitin conjugated to Gag could sterically disturb the highly 
ordered lattice of assembling Gag and thus exert a negative effect on distinct events during the budding 
process, and eventually on the auto-activation of the viral protease. Another possibility may be the 
direct masking of PR cleavage sites by bulky polyubiquitin adducts. This could contribute to the 
general processing defect observed in the context of L-domain mutants. In addition, the specific CA-SP1 
processing defect of the S40F mutant [30,31] could also be caused by Gag ubiquitination as particularly 
the CA-SP1 junction (
359
KARVL|AEAM) is the only cleavage site within Gag that has a lysine in 
close proximity. This notion is further supported by the observation that the S40F and ∆PTAP mutants 
display a defective Gag processing as well as enhanced levels of Gag ubiquitination, whereas the 
mutation of Ser-40 to Ala or Asn does neither affect Gag ubiquitination nor Gag processing [31,54]. 
A recent study revealed that the S40F mutation can occur naturally under anti-retroviral treatment, 
and even more, appears to correlate with high viral load, low CD4
+
 cell counts, and ultimate treatment 
failure [31]. Furthermore, the S40F mutation induces Gag-containing filopodia-like membrane 
protrusions which were speculated to trigger cell to cell transmission of HIV-1 under antiviral 
treatment. It could be hypothesized that an enhanced membrane association of Gag is the driving force 
behind the assembly of Gag in these filopodial structures. 
Taken together, we could demonstrate that the S40F mutation leads to the formation of a 
hydrophobic patch which increases the membrane binding of Gag and thus triggers its 
polyubiquitination, most likely by membrane resident ubiquitin ligases. This K48-linked 
polyubiquitination occurs independently of L-domain functions and the ESCRT-mediated budding 
process. Moreover, polyubiquitinated Gag that is incorporated into virions might account for the 
defects in CA-SP1 processing, virus morphogenesis, and infectivity observed for the S40F mutant. 
Conclusions 
Overall, these data support a novel model for an L-domain independent function of p6, at least  
observed for the S40 F mutant, which regulates the association of Gag with the plasma membrane, its 
K48-linked polyubiquitination, the efficiency in CA-SP1 processing, and thus the infectivity without 
affecting the release of progeny viruses. 
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